BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33765585)

  • 1. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
    Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
    Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
    Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
    Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
    Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
    Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
    Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
    J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells.
    Hong X; Li S; Li W; Xie M; Wei Z; Guo H; Wei W; Zhang S
    Biochem Biophys Res Commun; 2019 Jan; 508(3):986-990. PubMed ID: 30545630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
    Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
    J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
    Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
    Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.
    Estève MA; Carré M; Bourgarel-Rey V; Kruczynski A; Raspaglio G; Ferlini C; Braguer D
    Mol Cancer Ther; 2006 Nov; 5(11):2824-33. PubMed ID: 17121929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
    Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
    Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
    Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ClC-3 chloride channel associated with microtubules is a target of paclitaxel in its induced-apoptosis.
    Zhang H; Li H; Yang L; Deng Z; Luo H; Ye D; Bai Z; Zhu L; Ye W; Wang L; Chen L
    Sci Rep; 2013; 3():2615. PubMed ID: 24026363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
    Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
    J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.
    Wang F; Zhang L; Liu J; Zhang J; Xu G
    Aging (Albany NY); 2020 Jun; 12(11):11042-11060. PubMed ID: 32516753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
    Chu SW; Badar S; Morris DL; Pourgholami MH
    Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
    Giannakakou P; Sackett DL; Kang YK; Zhan Z; Buters JT; Fojo T; Poruchynsky MS
    J Biol Chem; 1997 Jul; 272(27):17118-25. PubMed ID: 9202030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.